Related Experiment Video
Updated: Dec 6, 2025
Calvarial Model of Bone Augmentation in Rabbit for Assessment of Bone Growth and Neovascularization in Bone Substitution Materials
Published on: August 13, 2019
Systemic osteoprotegerin does not improve peri-implant bone volume or osseointegration in rabbits
Joseph H Choi1, Zhiwei Wang1,2, Frederick P Ross1
1Hospital for Special Surgery, New York, New York, USA.
Abstract:
Anti-RANKL (receptor activator of nuclear factor kappa-B ligand) agents function by blocking the differentiation of osteoclasts, thereby proving useful in the clinical management of postmenopausal osteoporosis. The effects of such agents on osseointegration is less well understood. The purpose of the current study was to investigate whether osteoprotegerin (OPG), an osteoclast inhibitor, enhances the known anabolic effects of mechanical loading (VEH) and intermittent PTH (iPTH) using a well-established rabbit model of osseointegration. In the first set of experiments, OPG was administered either alone or combined with iPTH to study its effects on measured bone mass. The second set of experiments was conducted using a higher dosage of OPG (10 mg/kg) to explore its early impact at the cellular and molecular levels. All subjects had mechanical load applied to the implant on one extremity, and no load applied on the contralateral side. In the first set of experiments, OPG alone decreased peri-implant bone mass compared to the mechanical loading group, whereas OPG + iPTH increased peri-implant bone mass compared to the OPG group. In the second set of experiments, high-dose OPG significantly decreased osteoclast number (-74.3%) at 1 week. However, this effect was not sustained as osteoclast number returned to baseline by 2 weeks. These results suggest that systemic administration of OPG does not enhance osseointegration, but rather has a detrimental effect.
Insights
Osteoprotegerin (OPG) did not improve osseointegration in rabbits. While it initially reduced osteoclasts, OPG alone decreased bone mass and did not enhance anabolic effects with mechanical loading or PTH.
Area of Science:
- Biomedical Engineering
- Orthopedics
- Bone Biology
Background:
- Anti-RANKL agents, like osteoprotegerin (OPG), inhibit osteoclast differentiation and are used for osteoporosis.
- The impact of these agents on osseointegration remains unclear.
- Investigating OPG's role in osseointegration is crucial for understanding bone healing and implant success.
Purpose of the Study:
- To determine if osteoprotegerin (OPG) enhances osseointegration.
- To evaluate OPG's effects on the anabolic actions of mechanical loading (VEH) and intermittent parathyroid hormone (iPTH).
- To assess OPG's impact on bone mass and cellular/molecular changes during osseointegration.
Main Methods:
- A rabbit model of osseointegration was used with mechanical loading applied to one limb.
- Experiments involved administering OPG alone or with iPTH to measure bone mass.
- High-dose OPG was used in a second set to examine early cellular and molecular effects on osteoclasts.
Main Results:
- OPG alone decreased peri-implant bone mass compared to mechanical loading.
- OPG combined with iPTH increased peri-implant bone mass relative to OPG alone.
- High-dose OPG transiently reduced osteoclast numbers by 74.3% at 1 week, but numbers returned to baseline by 2 weeks.
Conclusions:
- Systemic OPG administration does not enhance osseointegration.
- OPG may have detrimental effects on peri-implant bone mass.
- Further research is needed to clarify OPG's role in bone healing around implants.
